Pfizer plans to buy Encysive after expiration of antitrust review

NEW YORK Pfizer declared its interest in buying Encysive Pharmaceuticals’ outstanding shares at $2.34 on the news of the expiration of its antitrust waiting period

Shares for Pfizer, according to published reports closed on Wednesday at $20.69, down 9 cents, while Encysive closed at $2.34. Revenue for shares of Pfizer is a reported $48.42 billion in 2007, while Encysive closed the year at $35.92 million.

According to published reports, the offer from Pfizer’s subsidiary Explorer Acquisition to buy shares expires at midnight eastern time, unless it were to be extended for any reason.

Login or Register to post a comment.